Key result
Baseline PCSK9 levels over 1011.3 ng/mL were associated with an increased risk of major cardiovascular adverse events in AMI patients with hypertension after PCI (HR 1.05; p<0.001).
Why the study?
Whether serum PCSK9 affects the prognosis of hypertension patients after PCI remained unknown.
Are elevated baseline PCSK9 levels associated with an increased risk of MACE in AMI patients with hypertension after PCI?
Cohort (n=2,350)
Are elevated baseline PCSK9 levels associated with an increased risk of MACE in AMI patients with hypertension after PCI?
Hazard Ratio: 1.05
p-value: p=<0.001
Elevated baseline PCSK9 levels are associated with a higher risk of MACE and correlate with coronary disease severity in hypertensive patients with AMI undergoing PCI.
May inform post-PCI risk stratification in hypertensive AMI; hypothesis-generating and requires prospective validation before clinical use.
Whether serum proprotein convertase subtilisin/kexin type 9 (PCSK9) affects the prognosis of patients after the percutaneous coronary intervention (PCI) in hypertension patients remains unknown. A total of 2350 acute myocardial infarction (AMI) subjects with hypertension after PCI were enrolled. Subjects were under 30-months follow-up and divided into the major cardiovascular adverse event (MACE) Group and the non-MACE Group. Cox regression analysis were performed for the risk factors of occurrence of MACE. The relationship between the level of PCSK9 and Gensin score was analyzed by Pearson correlation. Two hundred and thirty-two patients were divided to the MACE Group. Age over 55 (hazard ratio (HR) = 2.52; p = 0.032), smoking (HR = 1.02; p < 0.001), diabetes mellitus (HR = 1.35; p < 0.001) and PCSK9 levels over 1011.3 ng/mL (HR = 1.05; ptdf < 0.001) were risk factors of occurrence of MACE. Baseline levels of PCSK9 was significantly related with Gensini score in ST segment elevation myocardial infarction (STEMI) patients ( r = 0.51), all patients ( r = 0.37) and non-STEMI patients ( r = 0.34, p < 0.001). A high baseline PCSK9 level was the risk factor of poor prognosis of AMI patients with hypertension after PCI. PCSK9 levels were associated with the Gensini score in STEMI patients. Trial registration: This trial was registered at clinicaltrials.gov as NCT04100434.
No takes yet. Share an insight, caveat, or question.
Wen et al. (2022) conducted a cohort in Acute myocardial infarction with hypertension after PCI (n=2,350). Elevated baseline PCSK9 levels (>1011.3 ng/mL) vs. Lower baseline PCSK9 levels was evaluated on Major cardiovascular adverse event (MACE) (HR 1.05, p=<0.001). Baseline PCSK9 levels over 1011.3 ng/mL were associated with an increased risk of major cardiovascular adverse events in AMI patients with hypertension after PCI (HR 1.05; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: